Ingredients for the prevention or treatment of diabetes, including long-term insulin combination and long-term insulin and insulin combination, as well as diabetes treatment procedures. The parallel effect of long-acting similar peptide and long-acting insulin copolymer inhibited the increase of insulin intake, vomiting and nausea caused by the use of insulin insulin peptide, and reduced the required insulin dose,This has greatly improved drug compliance. Use of drug ingredients to reduce the side effects of pancreatic B cells on diabetic patients, It includes a similar combination of long-acting insulin and a similar combination of long-acting insulin, and a program to reduce the side effects of insulin B cells on diabetic patients,This includes the component management phase, which is characterized by reduced side effects, such as dysfunction of pancreatic B cells related to the development of diabetes, decreased pancreatic B cell mass, lipotoxicity or glucose poisoning. Claim 2: pharmaceutical ingredients used to reduce side effects of one or more pancreatic B cells selected from this group, including: lipotoxicosis, glucose poisoning, pancreatic B cell dysfunction and pancreatic B cell quality decline in diabetic patients,It includes: a combination of insulin with similar durable function formed by the combination of similar insulin and biological durable materials, which can prolong the activity time of insulin like through covalent combination or combination； and a composite composed of insulin and insulin with durable function By combining a dioxygoin free peptide with a biological adaptive substance that can extend the activity of dioxygoin free peptide through covalent linkage or binding. Requirement 6: composition according to requirement 1 or 2,Insulin peptide was selected from GLP-1 substances such as GLP-1, exendina-3 and exendina-4, and the promoters of these substances came from these substances, fragments of these substances, variants and combination
